​

Viridian Therapeutics (VRDN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Viridian Therapeutics Revenue Highlights

Latest Revenue (Y)

$70.85M

Latest Revenue (Q)

$141.00K

Main Segment (Y)

License

Viridian Therapeutics Revenue by Period

Viridian Therapeutics Revenue by Year

DateRevenueChange
2025-12-31$70.85M23359.93%
2024-12-31$302.00K-3.82%
2023-12-31$314.00K-82.28%
2022-12-31$1.77M-40.20%
2021-12-31$2.96M182.19%
2020-12-31$1.05M-76.46%
2019-12-31$4.46M-46.80%
2018-12-31$8.39M109.49%
2017-12-31$4.00M19.96%
2016-12-31$3.34M31.48%
2015-12-31$2.54M-41.25%
2014-12-31$4.32M0.08%
2013-12-31$4.32M-2.03%
2012-12-31$4.41M-

Viridian Therapeutics generated $70.85M in revenue during NA 2025, up 23359.93% compared to the previous quarter, and up 6747.52% compared to the same period a year ago.

Viridian Therapeutics Revenue by Quarter

DateRevenueChange
2026-03-31$141.00K6.82%
2025-12-31$132.00K-99.81%
2025-09-30$70.57M93993.33%
2025-06-30$75.00K4.17%
2025-03-31$72.00K-
2024-12-31$72.00K-16.28%
2024-09-30$86.00K19.44%
2024-06-30$72.00K-
2024-03-31$72.00K-
2023-12-31$72.00K-
2023-09-30$72.00K-
2023-06-30$72.00K-26.53%
2023-03-31$98.00K-6.67%
2022-12-31$105.00K-91.21%
2022-09-30$1.20M366.80%
2022-06-30$256.00K18.52%
2022-03-31$216.00K0.93%
2021-12-31$214.00K2.88%
2021-09-30$208.00K-80.92%
2021-06-30$1.09M-24.88%
2021-03-31$1.45M2587.04%
2020-12-31$54.00K100.00%
2020-09-30--100.00%
2020-06-30$168.00K-79.71%
2020-03-31$828.00K-5.91%
2019-12-31$880.00K26.62%
2019-09-30$695.00K-72.35%
2019-06-30$2.51M575.81%
2019-03-31$372.00K-21.85%
2018-12-31$476.00K-49.58%
2018-09-30$944.00K-56.74%
2018-06-30$2.18M-54.39%
2018-03-31$4.78M301.34%
2017-12-31$1.19M-26.92%
2017-09-30$1.63M127.16%
2017-06-30$718.00K55.41%
2017-03-31$462.00K-38.89%
2016-12-31$756.00K-14.96%
2016-09-30$889.00K1.72%
2016-06-30$874.00K6.85%
2016-03-31$818.00K24.13%
2015-12-31$659.00K31.54%
2015-09-30$501.00K-31.74%
2015-06-30$734.00K13.80%
2015-03-31$645.00K-1.45%
2014-12-31$654.52K-49.69%
2014-09-30$1.30M2.15%
2014-06-30$1.27M16.74%
2014-03-31$1.09M0.03%
2013-12-31$1.09M10.88%
2013-09-30$983.59K-10.82%
2013-06-30$1.10M-3.20%
2013-03-31$1.14M-

Viridian Therapeutics generated $141.00K in revenue during Q1 2026, up 6.82% compared to the previous quarter, and up 195.83% compared to the same period a year ago.

Viridian Therapeutics Revenue Breakdown

Viridian Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
License$70.00M----
Collaboration$849.00K----
Collaboration Revenue-$300.00K$300.00K$1.80M$2.96M
Grant-----

Viridian Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (98.80%), and Collaboration (1.20%).

Quarterly Revenue by Product

Product/ServiceMar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20
License$6.00K-$70.00M-----------------
Collaboration$135.00K$279.00K$570.00K-----------------
Collaboration Revenue---$100.00K$100.00K$100.00K$100.00K$100.00K-$100.00K$100.00K$100.00K$100.00K$1.20M$300.00K$200.00K$208.00K--$54.00K
Grant--------------------
Collaboration Revenue, Related Party-----------------$1.09M$1.45M-

Viridian Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Collaboration (95.74%), and License (4.26%).

Viridian Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RCUSArcus Biosciences$247.00M$17.00M
GLPGGalapagos$239.70M$62.43M
IBRXImmunityBio$113.29M$44.21M
VRDNViridian Therapeutics$70.85M$141.00K
OCULOcular Therapeutix$51.82M$10.79M
QUREuniQure$16.10M$3.56M
CLDXCelldex Therapeutics$1.54M$15.00K
GPCRStructure Therapeutics--
COGTCogent Biosciences--
EWTXEdgewise Therapeutics--
VERAVera Therapeutics--

VRDN Revenue FAQ

What is Viridian Therapeutics’s yearly revenue?

Viridian Therapeutics's yearly revenue for 2025 was $70.85M, representing an increase of 23359.93% compared to 2024. The company's yearly revenue for 2024 was $302K, representing a decrease of -3.82% compared to 2023. VRDN's yearly revenue for 2023 was $314K, representing a decrease of -82.28% compared to 2022.

What is Viridian Therapeutics’s quarterly revenue?

Viridian Therapeutics's quarterly revenue for Q1 2026 was $141K, a 6.82% increase from the previous quarter (Q4 2025), and a 95.83% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $132K, a -99.81% decrease from the previous quarter (Q3 2025), and a 83.33% increase year-over-year (Q4 2024). VRDN's quarterly revenue for Q3 2025 was $70.57M, a 93993.33% increase from the previous quarter (Q2 2025), and a 81958.14% increase year-over-year (Q3 2024).

What is Viridian Therapeutics’s revenue growth rate?

Viridian Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 22463.38%, and for the last 5 years (2021-2025) was 2291.12%.

What are Viridian Therapeutics’s revenue streams?

Viridian Therapeutics's revenue streams in c 25 are License, and Collaboration. License generated $70M in revenue, accounting 98.80% of the company's total revenue Collaboration generated $849K in revenue, accounting 1.20% of the company's total revenue

What is Viridian Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Viridian Therapeutics was License. This segment made a revenue of $70M, representing 98.80% of the company's total revenue.